

# Anxiety and Depression in Women with Polycystic Ovary Syndrome (PCOS)

**Lapasova Zebiniso Khidirovna**

*Lecturer of Pathophysiology Department of the Samarkand State Medical University*

**Indrajeetsingh Meharbansingh Pothiwal**

*Student of International Faculty of the Samarkand State Medical University*

**Abstract:** Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects premenopausal women, characterized by chronic anovulation and hyperandrogenism. As far as women are concerned, PCOS is the most common hormone disorder that manifests in menstrual cycle irregularities and multiple little cysts on the ovaries resulting hormonal imbalances to a great extent affecting their overall health — physical, mental or otherwise. Anxiety and depression are the most commonly associated comorbidities with PCOS, both of which tend to co-exist, furthering the burdensome effect of this syndrome.

**Keywords:** PCOS, population with hormonal health issues, physical and mental health, Headaches, Psychological factors, Therapy, Insulin Resistance, Genetic factors, Patient education, Anxious disorder

## Prevalence and Etiology:-

Rates of anxiety and depression are believed to be 30–50% in women with PCOS, compared with 15–20% in the population. This much higher rate would indicate a very strong connection between PCOS and mental health issues.

The causes of anxiety and depression in women with PCOS are different and is not so clear-cut, also includes both biological and psychological factors:-

- **Hormonal Imbalances:** PCOS is related to excess levels of androgens — male sex hormones that include testosterone. Adrenal androgens have been also suggested to have a role in regulating mood, and its possible dysregulation may implicate it to mood disorder.
- **Insulin Resistance** — Insulin resistance is a hallmark of PCOS and can cause more inflammation and changes in neurotransmitter function (the things that are going on in your brain) which may play a role in anxiety and depression.
- **Blessing:- Neuroendocrine Dysfunction** — PCOS implicated in the alternations of hypothalamic-pituitary axis (HPA) and sympathetic nervous system that are responsible for regulating stress response. These disruptions can unfortunately result in more anxiety and behaviors.
- **Genetic Factors:** — Genetic predispositions could lead to development of both PCOS and mental health disorders which indicate involvement of common genetic basis.
- **Psychological:-** Women with PCOS can suffer from depression and anxiety related to infertility, physical symptoms of the disease or social stigma. These stressors can even lead to negative occurrences like anxiety and depression.

## Clinical Manifestation :-

Women with PCOS can present a spectrum of anxiety and depression symptoms including:

### **Anxiety:-**

- Frequent or exaggerated anxiety and worrying
- Always feeling on edge/being hyper vigilant
- Difficulty concentrating, making decisions
- Muscle tension or headaches
- Sleep disturbances
- Hiding from People

### **Depression :-**

- Lasting feelings of sadness or mood swings
- Losing interest in things that were once enjoyed
- Changes in Appetite/Sleep patterns
- Worthlessness or feeling hopeless
- Problems such as: lack of attention to detail, multiple topics that you think make it difficult to remember
- Difficult focusing or making decisions
- Fatigue or loss of energy

### **Impact and Consequences:-**

Anxiety and depression affect the female population with PCOS; consequently, it has an effect on the overall health-related quality of life. They can:

- Aggravate physical symptoms of PCOS (menstrual irregularities, acne)
- impair daily functioning such as work, relationships, and social activities.
- Heightened risk of more mental health problems, such as eating disorders or drug use
- Decrease adherence to PCOS medical treatments
- Have a negative impact on fertility outcomes
- Deteriorate the quality of life as a whole

### **Management and Treatment:-**

A holistic management of anxiety and depression in women with PCOS must involve coping strategies for the underlying biological determinants alongside a psychological impact. Treatment options Facial skin Clear Liquid like.

### **Medications :-**

Depression Treatments: -Medication that includes selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine, serotonin neurotransmitter effect on depression and tricyclic antidepressants.

Anxiolytics:- Short term anxiolytic agents ie benzodiazepines and Buspirone may help reduce anxiety symptoms.

### **Therapy :-**

Cognitive-behavioral therapy (CBT):- The aim of CBT is to get rid of negative thought patterns and behaviors that lead to anxiety and depression.

Mindfulness-Based Stress Reduction (MBSR) – MBSR teaches mindfulness skills that are designed to help someone cope with stress and better regulate emotions.

Interpersonal therapy (IPT): IPT focuses on resolving problems and issues in relationships that might be a contributing factor to mental health symptoms.

### **Lifestyle Modifications:-**

You may also include this routines for better results Regular exercise:- Exercise helps to blow off frustration and stress.

- Eat well:- Consuming a healthy, balanced diet can aid overall health.
- Get enough sleep:- Try to get 7-9 hours of restful sleep each night.
- Dynamic stress management techniques:- Such as yoga, meditation, or going into the nature itself.

### **Role of PCOS Management:-**

Successful PCOS management is critical to building better health in body and mind. The following are considered the ways you can reduce your anxiety and depression.

- Insulin-sensitizing medications:- Medications such as metformin help to improve insulin resistance and correct androgen, which may mitigate at least some of the neuroendocrine and hormonal underpinnings for anxiety/depression.
- Hormonal therapies: Hormonal medications can regulate menstrual cycles, lower androgen levels, improve signs of PCOS, and may also benefit mental health.
- Weight loss: in obese or overweight women with PCOS, losing weight through lifestyle changes or bariatric surgery can make insulin sensitivity better and lessen the severity of anxiety and depression symptoms.

### **Discussion and Future Directions:-**

Screening and Early Detection:-

Therefore, since anxiety and depression are common among women with PCOS, these individuals should be periodically screened for possible mental health problems. Healthcare providers should use validated screening tools such as the Patient Health Questionnaire (PHQ-9) or Generalized Anxiety Disorder (GAD-7) scale when appropriate in their clinical decision making. The earlier we can identify and treat these kids as possible — to prevent lasting damage.

### **Individualized treatment approaches:**

Management of anxiety and depression among women with PCOS may require a personalised approach considering individual needs, preference. A treatment plan should be individualized, and take into account the severity of symptoms, any concomitant medical issues and personal history. An optimal outcome can only be achieved by a team effort in which the patient plays an important role as well.

### **Role of Patient Education and Support:-**

It is important to educate women with PCOS about the relationship between anxiety, depression and PCOS. For example, patient education programs can assist with learning to recognize symptoms, identifying strategies for symptom management and support resources in the community. Support groups and online communities will help women with PCOS to not feel alone — which can enhance feelings of stigma.

Forthcoming Research and Future Approaches :- Current research are trying to unravel the sophisticated relationship between PCOS and mental health disorders. Future directions include:

Exploration of specific genetic variants- Discovery of genetic markers linked to the high prevalence and risk of anxiety and depression in PCOS could open the door for personalized prevention interventions and treatment.

- Lifestyle interventions:- future long-term studies with comprehensive lifestyle interventions, including changes in diet, exercise and physical activity, stress management strategies, and sleep optimization on mental health outcomes among women with PCOS.
- Targeted treatments:- Specific pharmacologic interventions that address the underlying neuroendocrine and hormonal disturbances contributing to anxiety and depression in PCOS require further development.
- Technology integration: Digital health tools like mobile apps and online platforms might offer accessible and individually-tailored support for depression and anxiety control, among women with PCOS.

### **Role of Family and Peers:-**

Family members and friends have a big part to play in the ways they support women with PCOS, experiencing anxiety and depression. Effective mental health outcomes can be achieved by offering emotional support, promoting healthier coping mechanisms and reducing stigma. A greater role for family & peers in planning authorities and support mechanisms, just as often happens in physical health.

### **Long-Term Monitoring and Prevention of ischemic stroke**

Anxiety and depression in women with PCOS seems to be a chronic condition which require long term follow up and management. Consistent monitoring of mental health symptoms, compliance with medication and even lifestyle choices are needed to prevent slip-backs and guarantee continued progress. Furthermore, there is an urgent need for healthcare providers to concentrate on preventive strategies which should include promotion of healthy lifestyle, reduction in stress and prompt identification and treatment of women predisposed to the development of mental health disorders.

### **Conclusion :-**

IT is a relatively new treatment for ITW/OCD, with promising results in open-label studies and controlled trials on other obsessive-compulsive spectrum disorders such as acne excoriée. Through interdisciplinary collaboration, cultural and social determinants of health, family and peer support, long-term follow-up and prevention strategies to address these mental health challenges can be implemented in the management of women diagnosed with PCOS.

### **References-**

1. Sarkisova V., Xegay R., Numonova A. ENDOCRINE CONTROL OF THE DIGESTION PROCESS. GASTROINTESTINAL ENDOCRINE CELLS //Science and innovation. – 2022. – T. 1. – №. D8. – C. 582-586.
2. Sarkisova V. ASPECTS OF THE STATE OF THE AUTONOMIC NERVOUS SYSTEM IN HYPOXIA //Science and innovation. – 2022. – T. 1. – №. D8. – C. 977-982.
3. Sarkisova V. et al. ESSENTIAL ROLE OF BRADIKININ IN THE COURSE OF BASIC LIFE PROCESSES //Science and innovation. – 2022. – T. 1. – №. D8. – C. 576-581.
4. Sarkisova V., Xegay R. Causes, Diagnosis, Conservative And Operative Treatment Of Uterine Myoma //Science and innovation. – 2022. – T. 1. – №. D8. – C. 198-203.
5. Vladimirovna S. V. Epidemiology, Theories Of The Development, Conservative And Operative Treatment Of The Endometriosis //The Peerian Journal. – 2023. – T. 15. – C. 84-93.
6. Vladimirovna S. V. About the Causes of Endometrial Hyperplasia and Forms of Endometrial Hyperplasia //Global Scientific Review. – 2023. – T. 12. – C. 25-32.
7. Саркисова В. В. Патогенетические отношения артериальной гипертензии и сопротивления инсулина //IQRO JURNALI. – 2023. – T. 2. – №. 1. – C. 727-731.

8. Sarkisova V., Numonova A., Xegay R. Аспекты Состояния Вегетативной Нервной Системы При Гипоксии //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 228-231.
9. Саркисова В., Абдурахманова К. Роль гормональных препаратов в терапии гиперпластических процессов эндометрия и в частности при миоме матки //Журнал вестник врача. – 2014. – Т. 1. – №. 1. – С. 167-168.
10. Sarkisova V., Regina X. РОЛЬ БРАДИКИНИНА В ПРОТЕКАНИИ ОСНОВНЫХ ЖИЗНЕННЫХ ПРОЦЕССОВ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 587-593.
11. Sarkisova V., Lapasova Z., Shernazarov F. O. Rakhmanov INFLAMMATORY DISEASES OF THE PELVIC WOMEN ORGANS. – 2023.
12. Sarkisova V. I. Alvi THE PROBLEM OF COMORBIDITY OF AFFECTIVE DISORDERS AND PERSONALITY DISORDERS. – 2023.
13. Vladimirovna S. V. et al. NEUROIMMUNOLOGICAL MECHANISMS OF THE FORMATION OF CHRONIC PAIN SYNDROME //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 2. – С. 45-49.
14. Nair V. G. et al. Endometriosis, Pathophysiology and Pathomorphology //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 2. – С. 222-230.
15. Victoria S. et al. In-Depth Analysis of Ibm Spss Application in Bone Regeneration //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 2. – С. 274-284.
16. MURALEEDHARAKURUP A. et al. MECHANISM OF ACTION OF BUSERELIN WITHIN THE TREATMENT OF INFERTILITY //International Journal of Alternative and Contemporary Therapy. – 2024. – Т. 2. – №. 3. – С. 38-43.
17. Vladimirovna S. V. et al. Changes in Internal Organs During Hypoxia: A Comprehensive Analysis //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 3. – С. 26-32.
18. Gadayevich K. A. et al. GENERAL PATHOGENESIS OF ALLERGIC REACTIONS //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 2. – С. 101-109.
19. Vladimirovna S. V. et al. HYPOXIA AND ASPHYXIA //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 2. – С. 37-44.
20. Sarkisova V. et al. INFLAMMATORY DISEASES OF THE PELVIC WOMEN ORGANS //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 331-335.
21. Sarkisova V., Regina X. THE ROLE OF BRADIKININ IN THE MAIN LIFE PROCESSES //Science and Innovation. – 2022. – Т. 1. – №. 8. – С. 587-593.
22. Vladimirovna S. V. et al. Hyperplastic Processes of the Endometrium: Issues of Etiopathogenesis, Clinic, Diagnosis, Treatment. Scholastic: Journal of Natural and Medical Education, 2 (3), 72–77. – 2023.
23. Sarkisova V., Numonova A., Xegay R. ANTIBIOTIC RESISTANCE OR FIGHTING THE GLOBAL THREAT OF THE XXI CENTURY //Science and Innovation. – 2022. – Т. 1. – №. 8. – С. 232-241.
24. Khidirovna L. Z., Bakhtiyorovich R. B. TRP Channels //International Journal of Integrative and Modern Medicine. – 2024. – Т. 2. – №. 5. – С. 179-186.
25. Sarkisova V. et al. BACTERIAL CYSTITIS //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 354-360.

26. Ikromovich H. S. et al. DEVELOPMENT OF CHRONIC CARDIAC DEFICIENCIES IN PATIENTS WITH CORONARY HEART DISEASE //International Journal of Cognitive Neuroscience and Psychology. – 2024. – Т. 2. – №. 5. – С. 63-67.
27. Фаррух Ш. Шерназаров Самандар, Курбаниязова ВЕ, Виктория Саркисова Владимировна.(2023). Клиническое значение микробиоты кишечника у новорожденных с геморрагической болезнью. IQRO, 2 (2), 867–877.
28. Sarkisova V. et al. CYTOKINE PROFILE IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 336-343.
29. ARTERIAL V. S. V. P. R. O. F. HYPERTENSION AND INSULIN RESISTANCE //IQRO JURNALI. – 2023. – Т. 2. – №. 1. – С. 685-691.
30. Sarkisova V., Alvi I. The problem of comorbidity of affective disorders and personality disorders //Science and innovation. – 2023. – Т. 2. – №. D5. – С. 170-177.
31. Sarkisova V. et al. BIPOLAR AFFECTIVE DISORDER (BAR) //Science and innovation. – 2023. – Т. 2. – №. D5. – С. 165-169.
32. Джуманов Б. и др. Применение инструментальных методов исследование в диагностике острого аппендицита у беременных //Журнал проблемы биологии и медицины. – 2014. – №. 1 (77). – С. 9-12.
33. Саркисова В., Абдурахманова К. Астено-вегетативные нарушения, оценка качества жизни у женщин климактерического возраста с гиперпластическими процессами в матке //Журнал вестник врача. – 2014. – Т. 1. – №. 1. – С. 163-166.